“Immunohistochemistry Subtyping Method Predicts Response to Neoadjuvant Chemotherapy and Long-Term Survival in Triple-Negative Breast Cancer Patients”

https://pubmed.ncbi.nlm.nih.gov/38117286

The immunohistochemistry subtyping method is a valuable predictor of response to neoadjuvant chemotherapy and long-term survival in patients with triple-negative breast cancer, and the post-treatment subtype should be considered for additional therapies.